Page last updated: 2024-11-08

2-hexynyladenosine-5'-n-ethylcarboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-hexynyladenosine-5'-N-ethylcarboxamide: adenosine receptor agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID164437
CHEMBL ID410873
SCHEMBL ID8102867
MeSH IDM0206579

Synonyms (34)

Synonym
adenosine-5'-n-ethyluronamide
gtpl373
EU-0100635
(2s,3s,4r,5r)-5-(6-amino-2-hex-1-ynyl-purin-9-yl)-n-ethyl-3,4-dihydroxy-oxolane-2-carboxamide
he-neca, solid, >=98% (hplc)
PDSP1_001061
PDSP2_000291
PDSP1_000974
LOPAC0_000635
PDSP2_001045
PDSP1_000292
PDSP2_000958
he-neca
NCGC00094002-02
NCGC00094002-01
2-hexynyl-5'-ethylcarboxamidoadenosine
H 8034
141018-30-6
(2s,3s,4r,5r)-5-(6-amino-2-hex-1-ynylpurin-9-yl)-n-ethyl-3,4-dihydroxyoxolane-2-carboxamide
2-hexynyl-neca
2-hexynyladenosine-5'-n-ethylcarboxamide
CHEMBL410873 ,
CCG-204723
beta-d-ribosuranuronamide, 1-(6-amino-2-(1-hexynyl)-9h-purin-9-yl)-1-deoxy-n-ethyl-
(2s,3s,4r,5r)-5-(6-amino-2-hex-1-ynyl-purin-9-yl)-n-ethyl-3,4-dihydroxy-tetrahydrofuran-2-carboxamide
SCHEMBL8102867
bdbm50453224
SR-01000075918-1
sr-01000075918
Q27071898
beta-d-ribofuranuronamide, 1-[6-amino-2-(1-hexyn-1-yl)-9h-purin-9-yl]-1-deoxy-n-ethyl-
2-hexynyl-5?-n-ethylcarboxamidoadenosine
DTXSID401276119
(2s,3s,4r,5r)-5-(6-amino-2-(hex-1-yn-1-yl)-9h-purin-9-yl)-n-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The arteries were precontracted with PGF2alpha (3 microM) and cumulative dose-response curves to either NECA itself, or the selective A2A agonists, 2-[4-2(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosi ne (CGS 21680) and 2-hexynyl-5'-N-ethylcarboxamidoadenosine (2HE-NECA) were obtained."( Prolonged exposure to 5'-N-ethylcarboxamidoadenosine (NECA) does not affect the adenosine A2A-mediated vasodilation in porcine coronary arteries.
Conti, A; Lozza, G; Monopoli, A, 1997
)
0.3
"We studied the dose-response effects of acute administration of the selective A1 adenosine receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA), the selective A2A agonists 2-hexynyl-5'-N-ethylcarboxamidoadenosine (2HE-NECA) and 2-[4-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine (CGS 21680) and the non-selective agonist N-ethylcarboxamidoadenosine (NECA) on plasma renin activity, atrial natriuretic peptide, cyclic guanosine 3',5'-monophosphate (cGMP) and endothelin-1 in spontaneously hypertensive rats."( Humoral effects of selective adenosine agonists in spontaneously hypertensive rats.
Alberti, C; Casati, C; Monopoli, A; Morganti, A; Ongini, E; Sala, C; Zanchetti, A, 1996
)
0.29
" Both humoral and hemodynamic parameters were determined 1 h after dosing in separate sets of animals."( Humoral effects of selective adenosine agonists in spontaneously hypertensive rats.
Alberti, C; Casati, C; Monopoli, A; Morganti, A; Ongini, E; Sala, C; Zanchetti, A, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
endonuclease IVEscherichia coliPotency3.98110.707912.432431.6228AID1708
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency7.94330.011212.4002100.0000AID1030
alpha-galactosidaseHomo sapiens (human)Potency12.58934.466818.391635.4813AID2107
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.28180.035520.977089.1251AID504332
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
survival motor neuron protein isoform dHomo sapiens (human)Potency1.12200.125912.234435.4813AID1458
M-phase phosphoprotein 8Homo sapiens (human)Potency28.18380.177824.735279.4328AID488949
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)4.38000.00020.552110.0000AID31417
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.89650.00011.20929.9700AID31859; AID32025; AID32027; AID32029; AID32031; AID32351
Adenosine receptor A3Rattus norvegicus (Norway rat)Ki0.02560.00030.91969.0000AID33337
Adenosine receptor A2aHomo sapiens (human)Ki0.00570.00001.06099.7920AID30654
Adenosine receptor A2bHomo sapiens (human)Ki0.00570.00021.635210.0000AID30654
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki0.00460.00061.353610.0000AID33573; AID33574
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki0.00380.00021.494010.0000AID33573; AID33574; AID33790; AID33935
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)EC50 (µMol)6.66700.00161.04608.2000AID31260; AID31265; AID31266
Adenosine receptor A2aHomo sapiens (human)EC50 (µMol)0.10500.00030.708110.0000AID30633
Adenosine receptor A2bHomo sapiens (human)EC50 (µMol)0.10500.00030.946110.0000AID30633
Adenosine receptor A2aRattus norvegicus (Norway rat)EC50 (µMol)0.59600.00000.11560.7200AID33769
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (61)

Processvia Protein(s)Taxonomy
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulusAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A2bHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
positive regulation of chemokine productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of interleukin-6 productionAdenosine receptor A2bHomo sapiens (human)
mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
positive regulation of mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
relaxation of vascular associated smooth muscleAdenosine receptor A2bHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2bHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
vasodilationAdenosine receptor A2bHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2bHomo sapiens (human)
protein bindingAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor activityAdenosine receptor A2bHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A2bHomo sapiens (human)
presynapseAdenosine receptor A2bHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID33337Binding affinity determined by displacement of specific binding of [125I]N-(4-amino-3-iodophenethyl)-adenosine in membranes of CHO cells stably transfected with the rat adenosine A3 receptor1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID30817Negative chronotropic activity via A2 Adenosine receptor was tested monitoring vasodilation in rat aorta1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-Alkynyl derivatives of adenosine-5'-N-ethyluronamide: selective A2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation.
AID228181Dose producing 10% decrease in heart rate of anesthetized spontaneously hypertensive rats (SHR's)1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID233405Ratio between Ki values of A1 and A2 receptors was determined1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-Alkynyl derivatives of adenosine-5'-N-ethyluronamide: selective A2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation.
AID31721Affinity for adenosine A1 receptor assayed in a competition assay in rat brain using [3H]-CHA as radioligand1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-Alkynyl derivatives of adenosine-5'-N-ethyluronamide: selective A2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation.
AID227038Selectivity as ratio of IC50 for A1 adenosine receptor compared to EC50 for A2 adenosine receptor1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID33427Affinity for the adenosine A2 receptor was evaluated in a competition assay in rat striatum using [3H]-CGS- 21680 as radioligand1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-Alkynyl derivatives of adenosine-5'-N-ethyluronamide: selective A2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation.
AID31417Inhibition of adenylate cyclase via adenosine A1 receptors in rat fat cell membranes1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID227155Selectivity as A1 adenosine receptors(high affinity) using [3H]CCPA compared to A2 adenosine receptors using [3H]-NECA in rat striatal membranes1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID31266Negative chronotropic activity via A1 Adenosine receptor was tested in spontaneously beating rat atria1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-Alkynyl derivatives of adenosine-5'-N-ethyluronamide: selective A2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation.
AID31859Binding affinity against adenosine A1 receptor from rat brain using [3H]CHA as a radioligand.1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.
AID30794Agonistic activity at adenosine A2 receptor1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID32031Binding affinity against low affinity component of adenosine A1 receptors from rat brain membranes using [3H]-DPCPX1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID25037Hydrophobicity index (k') (RP-HPLC)1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-Alkynyl derivatives of adenosine-5'-N-ethyluronamide: selective A2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation.
AID32029Binding affinity against high affinity component of adenosine A1 receptors from rat brain membranes using [3H]DPCPX1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID33769Functional activity against adenosine A2a receptor from rat aorta.1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.
AID32025Binding affinity against adenosine A1 receptor from rat brain membranes using [3H]cyclohexyladenosine as radioligand.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID30633Maximal NECA stimulation of adenylate cyclase via adenosine A2 receptor in human platelet membranes1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID234752Selectivity as the ratio of Ki value towards A1 receptor to that of A2a receptor.1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.
AID33574Binding affinity against adenosine A2 receptor from rat striatum using [3H]NECA as radioligand.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID231406Inhibition compared to inhibition by NECA (IC50 ratio) of rabbit platelet aggregation induced by ADP1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-Alkynyl derivatives of adenosine-5'-N-ethyluronamide: selective A2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation.
AID227156Selectivity as A1 adenosine receptors(high affinity) using [3H]-DPCPX compared to A2 adenosine receptors using [3H]NECA in rat striatal membranes1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID31260Adenosine A1 receptor mediated negative chronotropic activity in spontaneously beating rat atria1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors.
AID232497Relative affinities for Adenosine A1 and A2A receptors1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors.
AID33634Anti-aggregatory activity against adenosine A2A receptor from rabbit platelets. Potency ratio was reported with reference to the NECA IC50 of 0.2 uM.1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.
AID33790Binding affinity against adenosine A2a receptor from rat striatum using [3H]-CGS- 21680 as a radioligand.1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.
AID32027Binding affinity against adenosine A1 receptors from rat brain membranes using [3H]CCPA1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID33792Binding affinity to adenosine A2A receptor in rat striatal membranes by measuring displacement of specific [3H]-CGS- 21680 as radioligand1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID32351Displacement of [3H]CHA from Adenosine A1 receptor of rat brain1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors.
AID25036Hydrophobicity index (k'') (RP-HPLC pH 7.5)1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.
AID234758Selectivity determined as Ratio of Ki(nM) of A1 adenosine receptor to the Ki(nM) of A2 adenosine receptor1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID33770Vasorelaxation as Adenosine A2A receptor activity in rat aorta1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors.
AID30654Binding affinity against adenosine A2 receptor from human platelet membranes using [3H]NECA1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID232334Ratio of inhibition of ADP-induced rabbit platelet aggregation and Adenosine A2a receptor binding1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors.
AID33935Displacement of [3H]-CGS- 51680 from Adenosine A2A receptor of rat striatum.1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors.
AID33573Binding affinity against adenosine A2 receptor from rat striatal membranes with 50 nM CPA using [3H]-NECA1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID228183Dose producing 30% decrease in blood pressure of anesthetized spontaneously hypertensive rats (SHR's)1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID31885Binding affinity to adenosine A1 receptor in rat brain membranes by measuring displacement of specific [3H]PIA as radioligand.1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID31265Functional activity against adenosine A1 receptor from rat atria.1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.
AID1345685Human A1 receptor (Adenosine receptors)2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands.
AID1345618Human A2A receptor (Adenosine receptors)1999Biochemical pharmacology, Jan-01, Volume: 57, Issue:1
Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors.
AID1345721Human A2B receptor (Adenosine receptors)2005Biochemical pharmacology, Nov-25, Volume: 70, Issue:11
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors.
AID1345822Human A3 receptor (Adenosine receptors)2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands.
AID1345618Human A2A receptor (Adenosine receptors)1997British journal of pharmacology, Jun, Volume: 121, Issue:3
Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
AID1345618Human A2A receptor (Adenosine receptors)2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's20 (76.92)18.2507
2000's4 (15.38)29.6817
2010's1 (3.85)24.3611
2020's1 (3.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.20 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]